Peel Hunt reissued their buy rating on shares of Oxford BioMedica (LON:OXB) in a report released on Thursday morning, ThisIsMoney.Co.Uk reports.
Separately, Liberum Capital reissued a buy rating on shares of Oxford BioMedica in a research report on Friday, November 15th.
OXB opened at GBX 628 ($8.21) on Thursday. The firm has a market capitalization of $482.18 million and a PE ratio of -54.14. The company has a fifty day moving average price of GBX 566.14 and a two-hundred day moving average price of GBX 632.36. Oxford BioMedica has a 52 week low of GBX 461.50 ($6.03) and a 52 week high of GBX 793 ($10.36). The company has a debt-to-equity ratio of 10.55, a quick ratio of 1.80 and a current ratio of 2.21.
Oxford BioMedica Company Profile
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
See Also: Why are gap-down stocks important?
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.